Influence of pharmacy benefit practices on off-label dispensing of drugs in the United States

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 943-945

  Teagarden, J R ^a   Dreitlein, W B ^a   Kourlas, H ^a   Nichols, L ^a  

^a Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; GROWTH HORMONE; IMMUNOGLOBULIN;

ANEMIA; ANTICOAGULATION; BLEEDING; CENTRAL NERVOUS SYSTEM; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG DESIGN; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; FERTILITY; GENETIC DISORDER; HEALTH CARE POLICY; LUNG DISEASE; MEDICARE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEUTROPENIA; OFF LABEL DRUG USE; OPHTHALMOLOGY; PHARMACY BENEFIT MANAGEMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOLOGY; SHORT SURVEY; STANDARDIZATION; UNITED STATES;

HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; OFF-LABEL USE; UNITED STATES;

EID: 84859965604     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.367     Document Type: Short Survey

References (18)

1. Oliver, T.R., Lee, P.R. & Lipton, H.L. A political history of Medicare and prescription drug coverage. Milbank Q. 82, 283-354 (2004).
2. Dietz, M. Trends in employer-provided prescription-drug coverage. Mon. Labor Rev. August, 37-45 (2004).
3. Oberlander, J. The Political Life of Medicare (University of Chicago Press, Chicago, IL, 2003).
4. Centers for Medicare & Medicaid Services, Office of the Actuary. National health expenditures by type of service and source of funds, CY 1960-2009 〈https://www.cms.gov/NationalHealthExpendData/downloads/nhe2009. zip〉 (2009). Accessed 4 December 2011.
5. Daniels, N., Teagarden, J.R. & Sabin, J.E. An ethical template for pharmacy benefits. Health Aff. (Millwood) 22, 125-137 (2003).
6. Teagarden, J.R., Daniels, N. & Sabin, J.E. A proposed ethical framework for prescription drug benefit allocation policy. J. Am. Pharm. Assoc. (Wash). 43, 69-74 (2003).
7. A merican Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J. Clin. Oncol. 24, 3206-3208 (2006).
8. Radley, D.C., Finkelstein, S.N. & Stafford, R.S. Off-label prescribing among office-based physicians. Arch. Intern. Med. 166, 1021-1026 (2006).
9. Maher, A.R. et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306, 1359-1369 (2011).
10. 75% of U.S. health plans reimburse off-label uses of prescription drugs. Tufts CSDD Impact Report 11, 1-4 (2009).
11. Tillman, K., Burton, B., Jacques, L.B. & Phurrough, S.E. Compendia and anticancer therapy under Medicare. Ann. Intern. Med. 150, 348-350 (2009).
12. Mehr, S.R. The evolutionary role of the pharmacy and therapeutics committee in technology assessment. Manag. Care Interface 19, 42-45 (2006).
13. A cademy of Managed Care Pharmacy. Concepts in Managed Care Pharmacy Series - Formulary Management 〈http://www.amcp.org/WorkArea/DownloadAsset. aspx?id=9298> (2009). Accessed 2 December 2011.
14. Federal Register, 21 November 2000, Vol. 65, No. 225, 70246-70271.
15. Off-label prescriptions: patient safety first. Lancet Oncol. 12, 825 (2011).
16. Epstein, R. Against permititis: why voluntary organizations should regulate the use of cancer drugs. Minn. Law Rev. 94, 1-41 (2009).
17. Todd, A.E. No need for more regulation: payers and their role in balancing the cost and safety considerations of off-label prescriptions. Am. J. Law Med. 37, 422-443 (2011).
18. Liking, E. What new cancer pathway programs mean for the drug industry. In Vivo. 29, (2011).